NASDAQ
VRXAW
Last Price
US $0.0827
Valuation
Financial
Performance
Cash flow to debt coverage
Veraxa Biotech AG balance-sheet data unavailable; cash-flow debt coverage cannot be computed.
Free cash flow growth
Veraxa Biotech AG has insufficient data to evaluate this check.
Debt-to-equity ratio
Veraxa Biotech AG has insufficient data to evaluate this check.
Debt-to-equity trend
Veraxa Biotech AG has insufficient data to evaluate this check.
Net debt to EBITDA
Veraxa Biotech AG has negative EBITDA, making leverage ratio unreliable
Interest coverage
Veraxa Biotech AG interest expense data unavailable for the most recent period; interest coverage ratio cannot be reliably computed.
Profit margin growth
Veraxa Biotech AG has insufficient data to evaluate this check.
Current ratio
Veraxa Biotech AG has insufficient data to evaluate this check.
Return on assets
Veraxa Biotech AG's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Return on equity
Veraxa Biotech AG's return on equity of 0.00%, is lower than 15.00%, indicating bad performance
Earnings quality
Veraxa Biotech AG has insufficient data to evaluate this check.
Earnings stability
Veraxa Biotech AG has insufficient public price history to evaluate earnings stability.
Positive free cash flow
Veraxa Biotech AG has negative free cash flow, indicating the company is burning cash rather than generating it
Free cash flow yield
Veraxa Biotech AG has a free cash flow yield of 0.00%, which is below the 2.00% threshold, indicating limited cash return relative to market value
Earnings growth
Veraxa Biotech AG has insufficient data to evaluate this check.
Revenue growth
Veraxa Biotech AG has insufficient data to evaluate this check.
Return on invested capital
ROIC is unavailable for Veraxa Biotech AG; this check cannot be evaluated.
3-year revenue CAGR
Veraxa Biotech AG has insufficient revenue history to calculate 3-year revenue CAGR.
Revenue consistency
Veraxa Biotech AG has insufficient public price history to evaluate revenue consistency.
Return on equity consistency
Veraxa Biotech AG has insufficient public price history to evaluate ROE consistency.
Cash Flow Valuation (DCF)
Veraxa Biotech AG has insufficient data to evaluate this check.
Earnings yield (TTM)
Veraxa Biotech AG has insufficient data to evaluate this check.
EBITDA Valuation
Veraxa Biotech AG is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model
EV/EBITDA (FY)
Veraxa Biotech AG has negative or missing EBITDA, making EV/EBITDA ratio unreliable
PEG ratio (TTM/FY)
Veraxa Biotech AG has insufficient data to calculate the PEG ratio.
Price-to-book ratio (FY)
Veraxa Biotech AG has negative shareholder equity; price-to-book is not meaningful and the check fails
Price-to-sales ratio (TTM)
Veraxa Biotech AG has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue
Profit margin
Current Ratio
Capital Returns
-
Return on equity
ROIC: -
Valuation History
-
Price to Earnings
EV/EBITDA: -
Cash flow
Profit margin
-
Fair Value
Market $0.0827
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.